Status: Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.
Participants needed: 11,000
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Alnylam PharmaceuticalsUpdated: Jul 13, 2026Locations: 995
Eligibility criteria
Is 18 years or older for patients with established cardiovascular disease (CVD) [+3]
Has known history of secondary hypertension [+6]